Mode
Text Size
Log in / Sign up
N/A N=47 Randomized Single-blind Prevention

Effects of Hippotherapy on Physical Fitness and Attention in Cerebral Palsy

Cerebral Palsy · Physical Activity · Attention Disorder

Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcome: Primary: Change of Clinical Global Improvement(CGI) — -0.13; -0.09; 2.65; 3.87 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
hippotherapy (Behavioral)
Age
Pediatric · 6+ yrs
Sex
All
Sponsor
Samsung Medical Center
Primary completion
Feb 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Change of Clinical Global Improvement(CGI)
-0.13; -0.09; 2.65; 3.87
SECONDARY
Change of Attention
57.52; 57.70; 54.61; 55.39
SECONDARY
Change of Physical Activity(%)
1.86; -0.61; -1.58; 0.24; -0.28; 0.13
SECONDARY
Change of Peak Oxygen Uptake(VO2peak)
1.84; -0.09
SECONDARY
Change of Gross Motor Function Measure 66
2.24; 0.81
SECONDARY
Change of Physical Activity(Steps)
-37.97; 20.94
SECONDARY
Change of Resting Heart Rate(RHR)
-12.40; -0.62
SECONDARY
Change of Respiratory Exchange Ratio(RER)
0.04; 0.01
SECONDARY
Change of Heart Rate Recovery(HRR)
6.54; -2.15; 13.38; -5.54; 11.15; -3.80
SECONDARY
Change of Children Health Questionnaire Parent Form 50 (CHQ-PF50)
2.73; 2.08; 3.31; 2.50
SECONDARY
Change of Timed up and go(TUG)
-1.55; -1.33
SECONDARY
Change of 6 Minute Walk Test(6MWT)
37.22; 13.43
SECONDARY
Change of Blood Pressure(BP)
-1.30; 0.05; -1.55; 0.52
SECONDARY
Change of Pediatric Balance Scale(PBS)
2.48; 0.30
SECONDARY
Change of Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale
12.22; 11.13; 11.17; 10.26
SECONDARY
Change of Self-Esteem Scale
31.22; 32.48; 32.35; 33.34
SECONDARY
Change of PedsQL 4.0
60.73; 65.90; 69.70; 77.85; 70.22; 69.57
SECONDARY
Change of Continuous Performance Test 3rd Edition
59.00; 54.00; 52.57; 49.61; 71.70; 59.91
SECONDARY
Change of Quantitative Electroencephalography
0.384; -0.046; 0.522; -0.098; 0.501; 0.058

Summary

This research analyzes whether hippotherapy improves the physical activity, cardiopulmonary fitness, and attention in children with cerebral palsy and whether this enhances their general health and quality of life.

Eligibility Criteria

Inclusion Criteria

  • diagnosis of spastic CP
  • GMFCS level I-III
  • weight < 35kg
  • ability to walk independently with or without an assistive device
  • ability to comply with the study protocol and follow verbal directions

Exclusion Criteria

  • botulinum toxin injection within 3 months
  • orthopedic surgery within 1 year (difficulty performing one step instructions)
  • moderate to severe intellectual disability
  • uncontrolled seizure
  • poor visual or hearing acuity
  • patients who weigh more than 35 kg
  • hip dislocation
  • scoliosis more than 30 degrees
  • musculoskeletal surgery within 1 year
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03870893). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search